Vaxart value goal lowered to $1.50 from $6 at B. Riley

B. Riley analyst Mayank Mamtani lowered the agency’s value goal on Vaxart to $1.50 from $6 and retains a Impartial score on the shares. The goal drop displays a extra conservative estimate of ramp-up of Norovirus and peak market penetration from 35% to 24%, Mamtani tells traders in a analysis notice.

Revealed first on TheFly

See as we speak’s best-performing shares on TipRanks >>

Learn Extra on VXRT:

Supply hyperlink

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button